[Mechanisms responsible for myocardial damage progression in chronic Chagas' disease].
Dávila-Spinetti
Diego F
DF
Colmenarez-Mendoza
Humberto J
HJ
Lobo-Vielma
Liliana
L
D000493:Allopurinol / Q000008:administration & dosage / Q000627:therapeutic use; D000963:Antimetabolites / Q000008:administration & dosage / Q000627:therapeutic use; D002598:Chagas Cardiomyopathy / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D018450:Disease Progression; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004452:Echocardiography; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D009593:Nitroimidazoles / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D014344:Trypanocidal Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000963:Antimetabolites; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; D000493:Allopurinol; C009999:benzonidazole